Drug Trial Radar · NCT01070836
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
Last checked: Nov 20, 2026Latest source record: Sep 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35,895
Actual
Start
Mar 2010
Primary completion
Nov 2015
Study completion Nov 2015
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Feb 18, 2010
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV) (antibody negative) is lower than in participants who have detectable antibodies to JCV (antibody positive). The secondary objectives of this study are to: Estimate the incidence of PML in natalizumab-treated participants who are anti-JCV antibody negative and anti-JCV antibody positive, based on a meta-analysis of data obtained from this study and other data sources; Define the prevalence of anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving natalizumab within the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program; Determine changes in anti-JCV antibody status over time.
Conditions
- Relapsing Multiple Sclerosis
Interventions
natalizumabDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstrate that the incidence of PML in natalizumab-treated participants who do not have detectable antibodies to JC virus (JCV) (antibody negative) is lower than in patents who have detectable antibodies to JCV (antibody positive)Time frame: Up to 4 years
Locations
478 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Cullman, Alabama
Research Site
Tucaloosa, Alabama
Research Site
Anchorage, Alaska
Research Site
Flagstaff, Arizona
Research Site
Gilbert, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Scottsdale, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Fayetteville, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Sherwood, Arkansas
Research Site
Auburn, California
Research Site
Berkeley, California
Research Site
Carmel, California
Research Site
Carmichael, California
Research Site
Fountain Valley, California
Research Site
Fresno, California
Research Site
Fresno, California
Research Site
Fullerton, California
Research Site
La Jolla, California
Research Site
Loma Linda, California
Research Site
Los Alamitos, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Marina del Rey, California
Research Site
Modesto, California
Research Site
Newport Beach, California
Research Site
Northridge, California
Research Site
Palo Alto, California
Research Site
Pasadena, California
Research Site
Pasadena, California
Research Site
Redding, California
Research Site
Sacramento, California
Research Site
San Diego, California
Showing 40 of 478 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.